| Literature DB >> 34907348 |
Elliot Collins1, Caleb Martin1, Tyler Blomquist1, Katherine Phillips1, Stuart Cantlay1, Nathan Fisher2, Joseph Horzempa3.
Abstract
Insects are now well recognized as biologically relevant alternative hosts for dozens of mammalian pathogens and they are routinely used in microbial pathogenesis studies. Unfortunately, these models have yet to be incorporated into the drug development pipeline. The purpose of this work was to begin to evaluate the utility of orange spotted (Blaptica dubia) cockroaches in early antibiotic characterization. To determine whether these model hosts could exhibit mortality when infected with bacteria that are pathogenic to humans, we subjected B. dubia roaches to a range of infectious doses of Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, and Acinetobacter baumannii to identify the medial lethal dose. These results showed that lethal disease did not develop following infection of high doses of S. aureus, and A. baumannii. However, cockroaches infected with E. coli and K. pneumoniae succumbed to infection (LD50s of 5.82 × 106 and 2.58 × 106 respectively) suggesting that this model may have limitations based on pathogen specificity. However, because these cockroaches were susceptible to infection from E. coli and K. pneumoniae, we used these bacterial strains for subsequent antibiotic characterization studies. These studies suggested that β-lactam antibiotic persistence and dose was associated with reduction of hemolymph bacterial burden. Moreover, our data indicated that the reduction of bacterial CFU was directly due to the drug activity. Altogether, this work suggests that the orange-spotted cockroach infection model provides an alternative in vivo setting from which antibiotic efficacy can be evaluated.Entities:
Mesh:
Year: 2021 PMID: 34907348 PMCID: PMC8671488 DOI: 10.1038/s41598-021-03486-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
LD50.
| Insect model | Infecting strain | |||
|---|---|---|---|---|
| ND* | 5.82 × 106 | 2.58 × 106 | ND** | |
| 2.42 × 108 | 2.42 × 104 | 3.41 × 105 | 9.07 × 105 | |
ND not determined.
*50% lethality not produced with highest dose of 6.5 × 107 bacteria per roach.
**50% lethality not produced with highest dose of 2.3 × 107 bacteria per roach.
Figure 1Beta lactam recovery from B. dubia roaches over time. Cefotaxime (A), carbenicillin (B), or ampicillin (C) was injected into B. dubia roaches at the dose indicated. At the designated time points, hemolymph was extracted and was mixed with an anticoagulant. This material was dispensed onto a disk of sterile filter paper which was placed onto TSA containing E. coli that had been spread-plated. Following incubation, zones of inhibition were measured; to estimate the amount of antibiotic recovered, the values for the zones of inhibition generated from the recovered hemolymph were compared to a standard curve.
Half-life of cefotaxime, carbenicillin, and ampicillin for humans (as reported in the literature) and OS cockroaches.
| Cefotaxime | Carbenicillin | Ampicillin | |
|---|---|---|---|
| Humans | 1.1 h[ | 70 min[ | 1 h[ |
| Mice | 0.26 h[ | 0.3 h[ | 50 min[ |
| OS cockroaches | 2.3 ± 0.4 h | 3.5 ± 0.1 h | 2.6 h |
Minimum inhibitory concentrations (MIC) of cefotaxime, carbenicillin, and ampicillin for E. coli and K. pneumoniae BLS.
| Cefotaxime (μg/mL) | Carbenicillin (μg/mL) | Ampicillin (μg/mL) | |
|---|---|---|---|
| 0.0096 ± 0.0037 | 10 ± 0 | 50 ± 0 | |
| 0.0064 ± 0.0032 | 250 ± 0 | 500 ± 0 |
Values shown are mean ± SD.
Figure 2Treatment with cefotaxime reduces bacterial burden in a dose dependent manner that is specific to the activity of this drug. B. dubia cockroaches were infected with a lethal dose of E. coli (A), K. pneumoniae (BLS, Beta-lactam sensitive strain) (B), or K. pneumoniae (BAA-2146, Beta-lactam resistant) (C). Alternatively, B. dubia cockroaches were infected with a sublethal dose of E. coli (D) or K. pneumoniae BLS (E). At 24 h post infection, surviving cockroaches were euthanized and their hemolymph was isolated and mixed with an anticoagulant. This material was serially diluted and plated to enumerate CFU. CFU recovered from hemolymph was compared to input. These data were analyzed by a one way ANOVA and Tukey’s post hoc (A, P < 0.0001; P < 0.0001for 5 mg, 0.5 mg, 0.05 mg; P = 0.0784 for 0.005 mg cefotaxime. B, P < 0.0001; P < 0.0001for 5 mg, 0.5 mg, 0.05 mg; P < 0.001 for 0.005 mg cefotaxime. C, P = 0.1676. D, P < 0.0001; P = 0.0797 for 5 mg; P = 0.0007 for 0.5 mg; P = 0.3399 for 0.05 mg; P = 0.8688 for 0.005 mg cefotaxime. E, P < 0.0001; P < 0.0001 for 5 mg, 0.5 mg; P = 0.0001 for 0.05 mg; P < 0.005 mg cefotaxime).
Figure 3Log-reduction in CFU vs. Time > MIC exhibits a linear relationship for E. coli and K. pneumoniae BLS in the OS cockroach model. Data presented in Figs. 1 and 2 were used to extrapolate CFU reduction and Time > MIC for E. coli (A) or K. pneumoniae BLS (B). T > MIC was defined as the length of time detectible levels of antibiotic were recovered from the insects (the MIC for cefotaxime was lower than our limit of detection). The maximum value assigned for T > MIC was 24 h as this was the longest time-point from which we assayed for the presence of antibiotics from the OS cockroach hemolymph. GraphPad Prism was used to interpolate the standard curves from the mean Log-reduction in CFU values versus T > MIC for both E. coli (A) and K. pneumoniae BLS (B). The dashed lines represent the 95% confidence intervals. Adjusted R2 = 0.9839 (A) and 0.9856 (B).